Evernorth

Search documents
Can Optum Support UnitedHealth's Profit Amid Industry Headwinds?
ZACKS· 2025-07-28 14:51
Core Insights - UnitedHealth Group (UNH) is expected to report its second-quarter earnings on July 29, with a focus on its Optum platform, which may provide stability amid regulatory challenges and margin pressures in the health insurance sector [1][8] Optum Performance - Optum's diverse business model, encompassing pharmacy services, data analytics, and value-based care, positions UNH advantageously. In Q2 2025, Optum's revenues are projected to increase by 7.3% year-over-year, building on a 12% growth in 2024 and a 4.6% growth in Q1 2025 [2][8] - OptumHealth is enhancing its value-based care model, which aims to improve health outcomes while controlling costs, thereby mitigating the impact of rising claims in the sector [3] - OptumInsight is leveraging technology and data-driven services to enhance operational efficiencies for both external clients and UNH itself [3] Competitive Landscape - Elevance Health Inc (ELV) reported a 36.1% year-over-year increase in operating revenues for its Carelon services brand in Q2 2025, while overall operating revenues rose by 14.3% [5] - Cigna's health services division, Evernorth, saw adjusted revenues climb by 16% year-over-year in Q1 2025, with its second-quarter results expected on July 31 [6] Valuation and Earnings Estimates - UNH shares have declined by 44.5% year-to-date, compared to a 36.7% decline in the industry [7] - The forward price-to-earnings ratio for UNH is 12.2, above the industry average of 11.2, with a Value Score of A [9] - The Zacks Consensus Estimate for UNH's 2025 earnings is $21.15 per share, indicating a 23.5% decrease from the previous year [10]
UnitedHealth vs. Cigna: Which Insurer to Buy Amid Sector Turmoil?
ZACKS· 2025-07-11 15:20
Core Insights - UnitedHealth Group and Cigna are leading players in U.S. managed care insurance, facing challenges from rising medical costs and regulatory pressures [1][2] - Investors are concerned about profitability and guidance credibility in the current healthcare environment [1] UnitedHealth Group - UnitedHealth is a dominant force in managed care, supported by its Optum healthcare services and extensive Medicare Advantage and commercial insurance presence [3] - The company is experiencing increased pressure with medical loss ratios exceeding expectations due to higher utilization rates [3] - UnitedHealth withdrew its earnings outlook in May 2025, citing unexpected costs and missed earnings estimates in Q1 2025 [4] - The company generated operating cash flows of $5.5 billion in Q1 2025, a significant increase from $1.1 billion in the previous year [6] - UnitedHealth's dividend yield stands at 2.95%, higher than the industry average of 2.42% and Cigna's 1.96% [6] Cigna Group - Cigna has strategically divested from Medicare Advantage and related businesses, focusing on a commercial-heavy model that offers more predictable performance [7] - The company reported strong Q1 2025 results, benefiting from premium rate hikes and improved client relationships [7] - Cigna raised its full-year adjusted EPS guidance to at least $29.60, contrasting with peers that have lowered or withdrawn guidance [10] - Cigna's long-term debt-to-capital ratio is 39.56%, lower than the industry average and UnitedHealth's 42.87% [11] - Cigna's stock trades below Wall Street's average price target, indicating a potential upside of 22.5% [11] Valuation and Performance Comparison - Cigna's P/E ratio is 9.82, compared to UnitedHealth's 12.67, suggesting a more attractive risk-reward profile for Cigna [13] - Year-to-date, UnitedHealth shares have declined by 40.8%, while Cigna shares have increased by 11.8%, outperforming the broader industry [14] - Zacks Consensus Estimates favor Cigna, with upward revisions in EPS estimates, while UnitedHealth has seen multiple downward revisions [12] Conclusion - Cigna is positioned as a more favorable investment option due to its strategic focus on commercial business and proactive reforms, while UnitedHealth faces significant regulatory scrutiny and cost pressures [16][17]